Skip directly to content

NEW YORK CITY, NY, February 17, 2017 – Amid growing concerns about federal government commitments to the national HIV response, TAG applauds the New York City Department of Health and Mental Hygiene (DOHMH) for its radical expansion of the city’s sexual health clinics as hubs of HIV prevention, care, and treatment.

“Now more than ever, activism, community mobilization, and government leadership is required to end HIV as an epidemic in the United States,” said Mark Harrington, TAG’s executive director.

Webinar: Community mobilization – an assessment of mechanisms and barriers at CBOs and ASOs in nine U.S. metropolitan areas

Community mobilization: An assessment of mechanisms and barriers at CBOs and ASOs

This webinar featuring Kenyon Farrow, U.S. and Global Health Policy Director, presents the findings of TAG's new report, Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas. The webinar is produced in partnership with SpeakUP and HIV Prevention Justice Alliance.

LAM PEPFAR request

February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded countries and programs. The LAM test is a simple, useful diagnostic to detect TB in extremely vulnerable people with HIV


TAGline Spring 2017

An Activist’s Guide to Tuberculosis Diagnostic Tools

February 2017

Understanding tuberculosis (TB) diagnosis is critical to understanding why the world is currently failing to end TB. Nearly half of people with TB—over 4 million per year—are undiagnosed, leaving them ill and at risk of death and with the potential to transmit disease to others.  Closing this massive gap will require much better use of the current diagnostic methods, as well as research into faster, simpler, more accurate, and less expensive options.

An Activist’s Guide to Tuberculosis Diagnostic Tools provides an


February 2017

What are genotypes?

A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat and cure HCV.

HCV has six genotypes, labeled 1 through 6. There are also subtypes labeled with letters, for example, genotypes 1a and 1b. Most people are infected by a single, dominant genotype, but it is possible to have more than one at the same time (called a mixed infection).

Why do

New initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs.

NEW YORK, NY, January 30, 2017—Treatment Action Group (TAG) is pleased to announce the expansion of its Ending the Epidemic campaign to foster the development of bold epidemic-ending initiatives in some of the most heavily impacted regions of the United States.

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability

WASHINGTON, JANUARY 24, 2017—Public health groups, including Universities Allied for Essential Medicines (UAEM), Doctors Without Borders/Médecins Sans Frontières’ (MSF) Access Campaign, Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and Public Citizen, welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development

TAG Statement for the Record in Opposition to the Nomination of Tom Price for HHS Secretary

January 24, 2017

Treatment Action Group (TAG) releases this statement in strong opposition to the nomination of Representative Tom Price (R-GA) for Secretary of Health and Human Services (HHS). We urge critical community action and implore the Senate Finance Committee to challenge his nomination to helm an agency that plays an exceedingly important and complex role in ending the HIV, tuberculosis (TB) and hepatitis C (HCV) epidemics in the United States and ultimately around the world.

Tom Price’s

2016 TAGUpdate
December 1, 2016

2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
OCTOBER 25, 2016 – Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose. In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the